Managing and Navigating Patients with Polycythemia VeraVideo Categories: Polycythemia Vera
Supported through funding from Incyte
Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.
Dr. David S. Siegel discusses the importance of understanding the molecular biology of myeloma. Physicians can now look at and offer alternative treatments to patients that they identify will most likely do poorly with traditional treatment. He believes this area will develop quickly over the next 2 to 5 years.